Lacy L Sommer1, Rhonda E Schnur2, Warren R Heymann1. 1. Division of Dermatology, Cooper Medical School of Rowan University, Camden, New Jersey, USA. 2. Division of Genetics, Cooper Medical School of Rowan University, Camden, New Jersey, USA.
Abstract
BACKGROUND: Hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC) is an autosomal dominant syndrome due to mutation in fumarate hydratase. Patients with HLRCC frequently develop cutaneous and uterine leiomyomata and are at risk for renal cell carcinoma. Rarely, other malignancies have been reported. MAIN OBSERVATIONS: We report the development of basal cell carcinoma and melanoma in two siblings with genetically-confirmed HLRCC. CONCLUSIONS: It is unclear whether the development of melanoma and basal cell carcinoma in our patients is due directly to their mutations in the gene encoding fumarate hydratase, or genetic susceptibility at another unrelated locus, or whether these are incidental lesions. However this observation has implications for careful and routine skin surveillance in patients with HLRCC for lesions other than cutaneous leiomyomata.
BACKGROUND: Hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC) is an autosomal dominant syndrome due to mutation in fumarate hydratase. Patients with HLRCC frequently develop cutaneous and uterine leiomyomata and are at risk for renal cell carcinoma. Rarely, other malignancies have been reported. MAIN OBSERVATIONS: We report the development of basal cell carcinoma and melanoma in two siblings with genetically-confirmed HLRCC. CONCLUSIONS: It is unclear whether the development of melanoma and basal cell carcinoma in our patients is due directly to their mutations in the gene encoding fumarate hydratase, or genetic susceptibility at another unrelated locus, or whether these are incidental lesions. However this observation has implications for careful and routine skin surveillance in patients with HLRCC for lesions other than cutaneous leiomyomata.
Authors: D L Smit; A R Mensenkamp; S Badeloe; M H Breuning; M E H Simon; K Y van Spaendonck; C M Aalfs; J G Post; S Shanley; I P C Krapels; L H Hoefsloot; R J A van Moorselaar; T M Starink; J-P Bayley; J Frank; M A M van Steensel; F H Menko Journal: Clin Genet Date: 2011-01 Impact factor: 4.438
Authors: H J Lehtonen; M Kiuru; S K Ylisaukko-Oja; R Salovaara; R Herva; P A Koivisto; O Vierimaa; K Aittomäki; E Pukkala; V Launonen; L A Aaltonen Journal: J Med Genet Date: 2005-09-09 Impact factor: 6.318
Authors: M Llamas-Velasco; L Requena; H Kutzner; L Schärer; A Rütten; M Hantschke; B E Paredes; T Mentzel Journal: J Cutan Pathol Date: 2014-11-04 Impact factor: 1.587
Authors: Jorge R Toro; Michael L Nickerson; Ming-Hui Wei; Michelle B Warren; Gladys M Glenn; Maria L Turner; Laveta Stewart; Paul Duray; Ousman Tourre; Nirmala Sharma; Peter Choyke; Pamela Stratton; Maria Merino; McClellan M Walther; W Marston Linehan; Laura S Schmidt; Berton Zbar Journal: Am J Hum Genet Date: 2003-05-22 Impact factor: 11.025
Authors: Amalia Martinez-Mir; Benjamin Glaser; Gary S Chuang; Liran Horev; Arie Waldman; Danielle E Engler; Derek Gordon; Lynda J Spelman; Ioannis Hatzibougias; Jack Green; Angela M Christiano; Abraham Zlotogorski Journal: J Invest Dermatol Date: 2003-10 Impact factor: 8.551
Authors: Fred H Menko; Eamonn R Maher; Laura S Schmidt; Lindsay A Middelton; Kristiina Aittomäki; Ian Tomlinson; Stéphane Richard; W Marston Linehan Journal: Fam Cancer Date: 2014-12 Impact factor: 2.375